EUVIMEDEUVIMED entdecken
Crossref

SRS104 - A retrospective review of best medical therapy use in major lower limb amputation patients

James Hathaway, Than Dar, Chandini Chand, Kathrine Lee-A-Ping, Therese McCarthy, Marc Bailey, Patrick Coughlin

British Journal of Surgery · 27.03.2026 · 113 (Supplement_2)

DOI: 10.1093/bjs/znag018.101 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Surgery, online erschienen am 27.03.2026. Verfasst von James Hathaway und 6 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Best medical therapy (BMT), including antithrombotic and lipid-lowering treatment, is the standard of care for patients undergoing major lower limb amputation (MLLA), aiming to reduce major adverse cardiac events (MACE) and mortality. We assessed whether patients undergoing MLLA are receiving appropriate BMT.

Methods

This single-centre study included patients undergoing MLLA with clinical or radiological evidence of atherosclerosis. Medication use at admission and discharge was recorded. Triglyceride and LDL-C levels were measured at baseline, 3 months, and 6 months postoperatively.

Results

A total of 116 patients (81.9% male) were included. Comorbidities: diabetes (67.2%), hypertension (60.3%), heart failure (17.2%), and chronic kidney disease (28.5%). High-intensity statin use (75.0 to 82.5%, P = 0.0209) and ezetimibe increased significantly (6.9 to 11.3%, P = 0.0253). No patients were prescribed inclisiran, evolocumab, or icosapent ethyl, despite 10 meeting potential eligibility criteria. Antithrombotic use improved: full dose DOACs increased from 29.0 to 42.0% and warfarin from 0.9 to 2.7% (P < 0.001), COMPASS regimen increased from 12.9 to 21.4% (P = 0.0067). No statistical difference in single dose antiplatelet use was observed; patients receiving no antithrombotic therapy declined significantly (32 to 14, P < 0.001). Median LDL-C levels were 1.4 mmol/L baseline and at 6 months (P = 0.5443). Triglycerides levels increased 1.4 baseline to 2.0 mmol/L at 6 months (P = 0.1876).

Conclusions

While BMT prescribing improved following MLLA, adjunct lipid-lowering therapies remain underutilised reflected in no overall change in biochemical parameters. Broader implementation of full BMT is necessary to optimise cardiovascular risk reduction.

Zitieren

APA

Hathaway, J., Dar, T., Chand, C., Lee-A-Ping, K., McCarthy, T., Bailey, M., & Coughlin, P. (2026). SRS104 - A retrospective review of best medical therapy use in major lower limb amputation patients. British Journal of Surgery, 113(Supplement_2). https://doi.org/10.1093/bjs/znag018.101

Vancouver

Hathaway J, Dar T, Chand C, Lee-A-Ping K, McCarthy T, Bailey M, et al. SRS104 - A retrospective review of best medical therapy use in major lower limb amputation patients. British Journal of Surgery. 2026;113(Supplement_2). doi:10.1093/bjs/znag018.101

BibTeX
@article{Hathaway2026,
  author = {Hathaway, James and Dar, Than and Chand, Chandini and Lee-A-Ping, Kathrine and McCarthy, Therese and Bailey, Marc and Coughlin, Patrick},
  title = {SRS104 - A retrospective review of best medical therapy use in major lower limb amputation patients},
  journal = {British Journal of Surgery},
  year = {2026},
  volume = {113},
  number = {Supplement_2},
  doi = {10.1093/bjs/znag018.101}
}
Kostenlos starten →